<DOC>
	<DOC>NCT02426333</DOC>
	<brief_summary>The purpose of this study is to explore whether early abiraterone exposure is related to treatment response in patients with metastatic castration resistant prostate cancer. Furthermore to explore the relation between biomarkers and treatment response and drug exposure.</brief_summary>
	<brief_title>Optimizing Abiraterone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Patients with metastatic castration resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated Age â‰¥18 years Feasible to collect blood samples from Life expectancy of &gt; 6 months Measurable disease Able and willing to give written informed consent prior to screening and enrollment other anticancer therapies potent CYP3A4 inducers herbal medicine that could interfere with abiraterone exposure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>